Read more

February 11, 2021
1 min read
Save

Top in hem/onc: Breast cancer incidence, cancer risk in diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Female breast cancer has superseded lung cancer as the world’s most common cancer diagnosis, according to a recent report. It was the top story in hematology/oncology last week.

Another top story was about an analysis evaluating the risk for breast cancer in women with type 2 diabetes. Although this population did not present an overall increased risk for breast cancer, type 2 diabetes appeared to be associated with an increased risk for triple-negative breast cancer. Data further showed that metformin use for type 2 diabetes affected other breast cancer subtypes.

Mammogram snapshot of breasts of a female patient on the monitor with undergoing mammography test on the background.
Source: Adobe Stock

Read these and more top stories in hematology/oncology below:

Breast cancer supersedes lung as most common cancer diagnosis

Female breast cancer has become the most common cancer worldwide, with an estimated 2.3 million new cases diagnosed last year alone, according to the Global Cancer Statistics 2020 report. Read more.

Type 2 diabetes, metformin use impact risk for breast cancer subtypes

Women with type 2 diabetes and those who used metformin did not demonstrate an overall increased risk for breast cancer, according to an analysis of the Sister Study published in Annals of Oncology. Read more.

FDA clears IND application for stem cell therapy to treat type 1 diabetes

The FDA cleared an investigational new drug application for VX-880 (Vertex Pharmaceuticals), a stem cell-derived therapy for patients with type 1 diabetes, according to the agent’s manufacturer. Read more.

ASCO names molecular profiling of gastrointestinal cancer ‘Advance of the Year’

ASCO has named molecular profiling driving progress in gastrointestinal cancer as its Advance of the Year, acknowledging improvements in treatment that have resulted from molecular testing of patients’ tumors. Read more.

FDA approves Tepmetko for metastatic NSCLC subset

The FDA granted accelerated approval to tepotinib (Tepmetko, Merck/EMD Serono) for the treatment of certain patients with metastatic non-small cell lung cancer. Read more.